Tag: Drug Approvals
FDA Approves Personalized Tx for Metastatic Bladder Cancer
Balversa indicated for treatment of bladder cancer with FGFR3 or FGFR2 genetic alteration
FDA Approves Osteoporosis Tx for High-Risk Postmenopausal Women
Boxed warning states increased risks for cardiovascular death, stroke, heart attack
First Two-Drug Regimen Approved for HIV-1 Treatment
Dovato indicated for use in patients with no history of antiretroviral treatment
Ibrance Approval Expanded to Include Men With Breast Cancer
Kinase inhibitor approved in combination with endocrine therapy for male patients with breast cancer
FDA Approves Mavenclad for Treating Multiple Sclerosis
Treatment indicated for patients with relapsing-remitting, active secondary progressive MS
FDA Grants Approval for Hypogonadism Treatment
Jatenzo indicated for men with low testosterone due to certain conditions
Cimzia Injection Approved for New Inflammatory Arthritis Indication
FDA grants approval for first treatment for nonradiographic axial spondyloarthritis
FDA Approves Mayzent for Relapsing Multiple Sclerosis
Oral medication must be dispensed with important information about the drug's uses and risks
FDA OKs Tecentriq for Extensive-Stage Small Cell Lung Cancer
Drug now approved as first-line treatment to be used in combination with carboplatin and etoposide
FDA Approves First Immunotherapy Drug for Breast Cancer
Combo of Tecentriq and chemo given accelerated approval for triple-negative breast cancer
